Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 12, 2004 Brian Gorman	India Woos U.S. Biotech Companies Business abroad would bode well for investors and consumers.
The Motley Fool February 13, 2006 Brian Gorman	Albany Molecular's Royalty Squeeze Declining royalty revenue is likely to keep buffeting the contract services provider. Investors, take note.
The Motley Fool October 25, 2005 Brian Gorman	Albany Molecular's Mixed Bag The pharma's contract services side is improving, and Allegra royalties won't disappear. Even so, the company seems to be facing some tough times ahead. Investors, take note.
The Motley Fool May 11, 2006 Brian Gorman	Albany Molecular Stabilizes The chemistry services company's results are still slumping, but the worst appears to be over. Investors, take note.
The Motley Fool August 2, 2006 Brian Gorman	Albany Molecular Bouncing Back The small drug development services firm continues to progress with its turnaround. Investors, take note.
The Motley Fool November 10, 2006 Brian Gorman	Albany Molecular Plays the Odds Third-quarter results show that the chemistry services outfit continued to slog through some tough times. Heightened activity in its riskier side business suggests that 2007 might not bring a fatter bottom line.
The Motley Fool August 13, 2007 Andrew R. Vaino	Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow.
The Motley Fool July 22, 2004 Brian Gorman	Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent.
The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
The Motley Fool April 19, 2006 Brian Gorman	Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.
The Motley Fool March 28, 2005 Brian Gorman	A Passage to India? Changes in India's patent law could create new dynamics for the biotech and pharmaceutical industries. Investors should be on the lookout for the firms that seek to leverage these new opportunities.
Chemistry World December 1, 2014 Derek Lowe	Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool March 15, 2005 Lawrence Meyers	Pharma's Outsourcing Elixir Pharmaceutical Product Development saves the drug companies money. Solid financials suggest it's a prescription that's working. Investors who do their due diligence may also find a few dollars earned in their brokerage accounts as well.
Chemistry World June 2007	Student Book Reviews Chemistry for CSI Fans... At the Heart of Molecular Biology... A Broad Vista of Chemistry...Rings Are Not Just for Carbons... etc.
Chemistry World February 2012	Navigating the stormy seas of pharma In the pharmaceutical and biotech sector, quality navigation is becoming an essential process for identifying the best route to take in order to guide business effectively in a dramatically changing environment.
Chemistry World July 9, 2008 James Mitchell Crow	Pharma goes green to cut costs The pharmaceutical industry's current drive to curb spending is helping to speed the adoption of green chemistry, say experts in the industry.
The Motley Fool January 30, 2007 Ralph Casale	Molecular Devices Acquired Successful integration of companies like Molecular Devices and improvement of operating margins in the pharmaceutical contract research business unit should reward shareholders well.
Chemistry World November 2007	Book Reviews A review of books on: good clinical & laboratory practices, green chemistry, environmental chemistry, organic reactions in water, universal asymmetry, and molecular models for fluids.
Job Journal June 1, 2008 Alesia Benedict	Career Pros: Steering Clear of Offshore Outsourcing Jobs most likely to get shipped overseas, and how to avoid being left adrift.
Managed Care May 2004	Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs.
Inc. May 1, 2002 Kenneth Klee	The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies...
BusinessWeek November 10, 2003 Arlene Weintraub	Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk
Pharmaceutical Executive November 1, 2011	Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.
Chemistry World May 20, 2015 Katrina Kramer	Taking the lead on drug discovery Researchers from the UK have developed a straightforward strategy for making compounds that have the potential to become clinical drugs.
The Motley Fool February 28, 2008 Brian Lawler	Third Wave Making Tiny Ripples Small molecular-diagnostics developer Third Wave Technologies could be poised for big returns.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool December 15, 2004 Brian Gorman	Korea's Biotech Bet Korea's new facility could stimulate biotech research in Asia and lower costs for biotech companies.
The Motley Fool March 4, 2004 Brian Gorman	Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates.
The Motley Fool January 4, 2007 Ralph Casale	Picks and Shovels of Biotechnology Biotech investors will continue to venture into the dark mines of burgeoning pharmaceutical firms. There is certainly gold to be found in some of them, just remember to invest in some of the hardware stores of biotechnology along the way.
The Motley Fool June 22, 2005 Brian Gorman	Biotech's Global Agenda Bristol-Myers' recent outsourcing deal illustrates the global spread of biotech investments.
The Motley Fool April 8, 2004 Charly Travers	Indevus' Big Score (Maybe) A small biotech company lands a potentially rich deal.
The Motley Fool August 26, 2010 Travers & Jayson	Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing?
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
Chemistry World June 2010	Column: In the pipeline Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
The Motley Fool August 25, 2006 Brian Gorman	California's Drug Demands As the pressure grows on drugmakers from legislation, growth and consolidation in the outsourcing business seem likely.
The Motley Fool December 14, 2004 Charly Travers	Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor.
Bio-IT World Dec 2006/Jan 2007 Allison Proffitt	'An Unfortunate Storm': Tripos CEO Discusses Company Future Tripos announced that it has successfully sold its Discovery Informatics business to Vector Capital. Despite the company's difficulties, including a collapsed share price, president and CEO John McAllister is upbeat about the company's future.
The Motley Fool July 1, 2004 Brian Gorman	Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services.
Chemistry World April 21, 2009 Matt Wilkinson	Survival of the fittest While the pharmaceutical and biopharmaceutical sectors in general are outperforming broader stock market trends, many early stage companies are desperately trying to conserve cash and raise money to keep going.
Bio-IT World November 2006 Kevin Davies	Jubilant Curries Favor with BioPharma The explosion of drug discovery and development operations in India is epitomized by the success of several companies. Quietly building on a decade of experience in computational and bio-IT fields, JBL is rapidly pushing into a suite of drug discovery and development activities.
Chemistry World July 2008 William Bains	Beyond shareholder returns The author offers a new model for the pharmaceutical industry
The Motley Fool July 6, 2010 Luke Timmerman	Rising From the Ashes of Pfizer: The Michigan Contract Research Organization Cluster Many of the people who honed their skills inside Pfizer and other big companies have found new entrepreneurial outlets to keep doing what they do best at a growing array of contract research organizations.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool June 17, 2004 Selena Maranjian	Is Outsourcing Overblown? Maybe Americans aren't losing as many jobs overseas as we first thought.
Bio-IT World May 2006 Mark D. Uehling	Bio-IT World CTMS Survey An online survey of the clinical trial management system market reveals some divergences between how the pharma/biotech folks and the contract research folks see the CTMS landscape. Are our respondents happy with the CTMS landscape?
Chemistry World March 16, 2007	Testing Times for 'Mega-Pharma' A stern warning and gloomy forecast were delivered to the pharmaceutical industry at the Drug Discovery and Technology Summit in London.
Job Journal September 21, 2003 Marty Nemko	Biotech = Opportunity What this strong growth industry could offer you
Chemistry World September 9, 2011 Sean Milmo	King's College resurrects chemistry department King's College London is reopening its department of chemistry in 2012, eight years after it was closed due in part to a sharp drop in the popularity of the subject.